NewcelX Reports Promising Advances in Diabetes Treatment Using Advanced Biomaterials

NewcelX's Breakthrough Study in Type 1 Diabetes Treatment

NewcelX Ltd., a biotechnology company recognized for its innovative approaches to regenerative medicine, has recently unveiled significant findings from an international collaborative study. This research specifically focuses on advanced biomaterial strategies designed to improve the delivery of stem cell-derived islets for treating Type 1 Diabetes, all while eliminating the need for immunosuppressive therapies.

The research, which has gained recognition through peer review, appears in Diabetology, a prominent journal dedicated to diabetes research. It involved collaboration with prestigious academic institutions including the University of Technology Sydney, the University of Wisconsin–Madison, Monash University, Queensland University of Technology, and the Australian Foundation for Diabetes Research (AFDR). The study explored the capabilities of engineered scaffolds that incorporated extracellular matrix (ECM) derived from decellularized human pancreas, effectively evaluating its impact on the function of encapsulated islets generated from pluripotent stem cells.

This innovative approach has shown that integrating ECM within scaffolds significantly enhances the functional performance of implanted islets, achieving results comparable to those delivered without scaffolding. These promising outcomes highlight the vital role that biomaterials and tissue microenvironments play in supporting islet functionality, paving the way for safer and more effective delivery systems for future therapies.

The project received support from a Type 1 Diabetes research initiative spearheaded by AFDR, which in turn secured matched funding from the National Stem Cell Foundation of Australia. Additionally, it has received backing from Breakthrough T1D (previously known as JDRF), emphasizing the research's credibility within the scientific community.

Prof. Michel Revel, the Chief Scientific Officer of NewcelX, noted, "This research contributes to our understanding of how advanced biomaterials and tissue microenvironments can support engineered islet function. The findings align with our diabetes program's scientific principles, aiming at combining scalable stem cell-derived islets with methods to improve engraftment and retrievability, thus reducing reliance on chronic immunosuppressant drugs."

Understanding the urgency to develop viable cell therapies for Type 1 Diabetes, Prof. Bernard Tuch, also the Chief Scientific Officer of AFDR, remarked, "We are thrilled to make strides toward creating realistic solutions for Type 1 Diabetes with the support of both national and international partners."

Within NewcelX, the focus on Type 1 Diabetes manifests through their substantial commitment to advancing cell-based solutions. Their investigational product, IsletRx, is a stem cell-derived therapy crafted to restore insulin production in individuals reliant on insulin. The design incorporates exclusive cell differentiation protocols paired with protective and delivery-oriented features, all aimed at facilitating functional insulin release without necessitating widespread immunosuppression.

Ronen Twito, Executive Chairman and CEO of NewcelX, expressed pride in the study's findings, stating, "The positive results from this international collaborative study contribute to the ongoing enhancement of our technologies and guide our future development initiatives as we prepare for clinical trials."

NewcelX Ltd. (Nasdaq: NCEL), headquartered in Zurich, Switzerland, continues to position itself at the forefront of biotechnology, focusing on both cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The integration of advanced stem-cell technologies and biomaterials underlines its commitment to finding scalable solutions for conditions including Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes.

As always, NewcelX encourages stakeholders to remain updated on their progressive journey ahead. For more information, inquiries can be directed to investor relations or via their official website, underlining the company’s goal of advancing health solutions while adhering to the rigorous standards in both research and ethical considerations.